Details of the Drug Combinations

General Information of This Drug (ID: DMAVFG9)

Drug Name

5-Fluoro-2-deoxycytidine DMAVFG9

Synonyms

FdCyd; 5-Fluoro-2'-deoxycytidine

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
5-Fluoro-2-deoxycytidine + Idarubicin	DC4YEUP	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
------------------------------------------------------------------------------------

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
5-Fluoro-2-deoxycytidine + Tetrahydrouridine	DCL80OR	Tetrahydrouridine	Neoplasms	[3]
5-Fluoro-2-deoxycytidine + Tetrahydrouridine	DCMFHSG	Tetrahydrouridine	Adult Acute Myeloid Leukemia	[4]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00978250) A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU). U.S. National Institutes of Health.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	ClinicalTrials.gov (NCT00359606) 5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer
4	ClinicalTrials.gov (NCT01041443) 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes